Our Latest Stories
Our Science
June 10, 2025
Advancing Patient- and Provider-Centric Care in Multiple Myeloma
United by Purpose
Each of us plays a unique role in bringing our purpose to life.
About Us
Who We Are
We are an R&D driven,
AI-powered biopharma company committed to improving people’s lives and creating compelling growth.
Our Pipeline
5
Therapeutic areas
86
Compounds in clinical development
24
Clinical trials in phase 3
Pursue Progress. Discover Extraordinary.
Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.
Our Latest Press Releases
June 15, 2025
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
June 12, 2025
Media Update: EULAR: rilzabrutinib data in IgG4-related disease show reduction in flares and key disease markers; earns Fast Track designation in the US
June 9, 2025
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
June 7, 2025
Media Update: RAD: Dupixent data reinforce use in atopic dermatitis patients with skin of color